Synonyms: CTLA-8 | interleukin-17 alpha
Compound class:
Endogenous peptide in human, mouse or rat
Comment: Forms homodimeric ligand IL-17A, or heterodimeric IL-17A/IL-17F.
Species: Human
|
Immunopharmacology Comments |
IL-17A and IL-17F are important cytokines in the host response against many extracellular pathogens, but are also recognised to cause excessive tissue damage and exacerbate proinflammatory responses during autoimmunity. A molecular mechanism underlying IL-17's role in the disease process of RA is proposed by Ganesan and Rasool (2017) [10]. The IL-17 pathway is therefore a major therapeutic target in autoimmune diseases. A study that investigated the potential of using mesenchymal stromal cells (MSCs) as prophylactic and therapeutic agents against the acute rejection of lung grafts (in rats) identified MSC-induced down-regulation of IL-17A by allografts as a major contributor to reduced markers of inflammation and graft rejection [12]. In addition, MSC treatment promoted expression of PD-L1 on the grafts, which implicates a PD-1/PD-L1 driven inhibition of immune responses in the protective effects of MSC therapy. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Multiple sclerosis |
Disease Ontology:
DOID:2377 OMIM: 126200 Orphanet: ORPHA802 |
Approved therapy for MS. | |
Psoriasis |
Disease Ontology:
DOID:8893 |
Approved therapy for psoriasis. | |
Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Approved therapy for RA. | |
Psoriatic arthritis |
Disease Ontology:
DOID:9008 |
Approved therapy for PsA. | |
Ankylosing spondylitis |
Disease Ontology:
DOID:7147 |
Approved therapy for systemic ankylosing spondylitis. |